TrialALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis
Trial details
- Registry ID
- NCT03494504
- Phase
- Phase 3
Drug research
Reproxalap Ophthalmic Solution (0.5%)
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic ConjunctivitisNCT03494504 | ALDX | Phase 3 | Completed | 2018-11-05Actual |
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |